Condition: Multiple Myeloma · Sponsor: University of Heidelberg Medical Center
The goal of this clinical trial is to compare a maintenance therapy consisting of iberdomide and isatuximab with an iberdomide-only regimen. The trial is the subsequent maintenance therapy to GMMG-HD8/DSMM XIX trial for patients with newly-diagnosed multiple myeloma. Patients with newly-diagnosed multiple myeloma who underwent a similar quadruplet induction/consolidation therapy regimen followed by at least one ASCT can also be recruited. The main question it aims to answer is: • Will the addition of isatuximab lead to decreased amounts of measurable myeloma cells in the bone marrow after two years?
This description comes directly from the study's public registry record.
Hartmut Goldschmidt, Prof. · +49 6221 568198 · s.gmmg@med.uni-heidelberg.de
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Krems an der Donau | Krems, Austria | Recruiting |
| Ordensklinikum Linz Elisabethinen | Linz, Austria | Recruiting |
| Landeskrankenhaus Salzburg, Universitätsklinik für Innere Medizin III | Salzburg, Austria | Recruiting |
| Klinik Ottakring Wien | Vienna, Austria | Recruiting |
| Klinikum Wels-Grieskirchen GmbH | Wels, Austria | Recruiting |
| Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation | Aachen, Germany | Recruiting |
| Universitätsklinikum | Augsburg, Germany | Recruiting |
| Helios Klinikum Bad Saarow | Bad Saarow, Germany | Recruiting |
| Charité, III. Medizinische Abteilung | Berlin, Germany | Recruiting |
| Vivantes Klinikum Neukölln, Klinik für Hämatologie und Onkologie | Berlin, Germany | Recruiting |
| Helios Klinikum Berlin-Buch | Berlin, Germany | Recruiting |
| Onkologische Schwerpunktpraxis Bielefeld | Bielefeld, Germany | Recruiting |
+ 57 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06216158